Alector and GSK partnership to end after dementia, Alzheimer’s drug failures

GSK ends brain drug alliance with Alector

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

GSK ends dementia alliance with Alector after setbacks

GSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.

Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE)

GSK ends Alector neuroscience deal after antibody trial failures in Alzheimer’s and FTD, sending ALEC shares down.

GSK ends Alector alliance as both lead assets fail

GSK has ended its five-year neuroscience partnership with Alector after latozinemab and nivisnebart both failed to deliver on their potential.

GSK ends Alector neuroscience deal after trial failures - European Biotechnology Magazine

GSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks. The post GSK ends Alector neuroscience deal after trial failures appeared first on European Biotechnology Magazine.